A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.
Clinical trial NCT00197067 · COMPLETED
Trial details
- NCT number
- NCT00197067
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2004-03-15
- Primary completion
- 2005-04-26
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.